Elutia Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Elutia Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Elutia were recently set by distinguished experts, with an average mark of $5.00. If it reached this goal, it would represent a potential upside of approximately 26.9% from the previous closing price in February, 2024. The high end is $6.00, and the low is $4.00. If you are interested in ELUT stock, it is important to also consider its competitors.
26.90% Upside
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$159.62 | Buy/Sell | $178.42 | 16.53% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.53 | Buy/Sell | $118.92 | 17.64% |
SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$335.61 | Buy/Sell | $353.16 | 9.20% |
MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.74 | Buy/Sell | $92.47 | 19.76% |
EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$86.43 | Buy/Sell | $91.18 | 12.23% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.13 | Buy/Sell | $44.86 | 12.14% |
SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.81 | Buy/Sell | £16.09 | 67.28% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$28.34 | Buy/Sell | $46.60 | 53.49% |
LMAT Stock Forecast | LeMaitre Vascular | Outperform |
18
|
$65.46 | Buy/Sell | $59.86 | 6.94% |
AORT Stock Forecast | Artivion | Buy |
12
|
$20.57 | Buy/Sell | $24.15 | 21.54% |